Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Xanomeline by Karuna Therapeutics for Alzheimer's Disease: Likelihood of Approval
Xanomeline is under clinical development by Karuna Therapeutics and currently in Phase II for Alzheimer's Disease. According to GlobalData, Phase...